Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Traditional methods for cancer therapy, including radiotherapy, chemotherapy, and immunotherapy are characterized by inherent limitations. Bacteria-mediated tumor therapy is becoming a promising approach in cancer treatment due to the ability of obligate or facultative anaerobic microorganisms to penetrate and proliferate in hypoxic regions of tumors. It is widely known that anaerobic bacteria cause the regression of tumors and inhibition of metastasis through a variety of mechanisms, including toxin production, anaerobic lifestyle and synergy with anti-cancer drugs. These features have the potential to be used as a supplement to conventional cancer treatment. To the best of our knowledge, no reports have been published regarding the most common tumor-targeting bacterial agents with special consideration of obligate anaerobes (such as Clostridium sp., Bifidobacterium sp.) and facultative anaerobes (including Salmonella sp., Listeria monocytogenes, Lactobacillus sp., Escherichia coli, Corynebacterium diphteriae and Pseudomonas sp). In this review, we summarize the latest literature on the role of these bacteria in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Bifidobacteria Expressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice
Wei, C., Xun, A. Y., Wei, X. X., Yao, J., Wang, J. Y., Shi, R. Y., Yang, G. H., Li, Y. X., Xu, Z. L., Lai, M. G., et al. (2016) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615581977 · Cited by 75
RetractedEstimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention
Ho, C. L., Tan, H. Q., Chua, K. J., Kang, A., Lim, K. H., Ling, K. L., Yew, W. S., Lee, Y. S., Thiery, J. P., & Chang, M. W. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0181-y · Cited by 303
Probiotic Strain Lactobacillus casei BL23 Prevents Colitis‐Associated Colorectal Cancer
Jacouton, E., Chain, F., Sokol, H., Langella, P., & Bermúdez-Humarán, L. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01553 · Cited by 249
Kamarajan, P., Hayami, T., Matte, B., Liu, Y., Danciu, T., Ramamoorthy, A., Worden, F., Kapila, S., & Kapila, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131008 · Cited by 214
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
Arthur, J. C., Gharaibeh, R. Z., Uronis, J. M., Perez-Chanona, E., Sha, W., Tomkovich, S., Mühlbauer, M., Fodor, A. A., & Jobin, C. (2013) · Scientific Reports · doi:10.1038/srep02868 · Cited by 118
Liu, R., & Proud, C. G. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.123 · Cited by 117
Clostridium spores as anti-tumour agents
Van Mellaert, L., Barbé, S., & Anné, J. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.02.002 · Cited by 101
Cited by
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89
“Various strategies have been attempted to target hypoxia, including genetically engineered anerobic bacteria [8] and bioreductive prodrugs [9], which are activated in hypoxic environments.”
BackgroundZahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
“Anaerobic bacteria can effectively colonize hypoxic tumor regions, making them potential candidates for bacteria-mediated tumor immunotherapy [196].”
Metadata
- Authors
- Dróżdż, M., Makuch, S., Cieniuch, G., Woźniak, M., & Ziółkowski, P.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 261
- Pages
- 118296
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3070832600
- Cited by
- 77
- References
- 14
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.